After rejecting ImmunityBio’s Anktiva last year, the FDA has cleared the drug as a treatment for bladder cancer, making it the company’s first commercial-stage product. Anktiva (nogapendekin ...

This year’s American Association of Cancer Research (AACR) annual meeting saw a clutch of new studies on therapeutic vaccines that suggest the approach is starting to gain traction, after years ...

UroToday - GU OncToday brings coverage of the clinically relevant content needed to stay at the forefront of the dynamic field of GU oncology and urology.

Yohann Loriot’s presentation at EAU 2025 highlighted the potential of combining systemic and intravesical therapies for high-risk non-muscle invasive bladder cancer (HR-NMIBC). While BCG remains the ...